| Morphosys de

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

06.10.2022

Luisa Ciccarelli

Luisa Ciccarelli

SVP, Global Head of Technical Operations

View biography

Tim Demuth

Tim Demuth, M.D., Ph.D.

Chief Research and Development Officer

View biography

MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

28.09.2022

press release

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

22.09.2022

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

19.09.2022

MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters

31.08.2022

press release

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

04.08.2022

voting rights

MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

03.08.2022

press release

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

01.08.2022

voting rights

1
2
3
4
5
6
7
8
9
…
Next page
Last page